POS0660 CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS
Volume: 80, Issue: Suppl 1, Pages: 572 - 573
Published: May 19, 2021
Abstract
Background: The Janus kinase-1 preferential inhibitor filgotinib (FIL) improved rheumatoid arthritis (RA) signs and symptoms in phase (P)3 trials. 1–3 RA elevates cardiovascular disease risk; statins are used to reduce risk. Objectives: To assess safety of statin and filgotinib coadministration across the clinical program. Methods: Patients (pts) meeting 2010 ACR/EULAR RA criteria in P2 DARWIN 1–2 (D1–2; NCT01888874 , NCT01894516 ), P3 FINCH 1–3...
Paper Details
Title
POS0660 CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS
Published Date
May 19, 2021
Volume
80
Issue
Suppl 1
Pages
572 - 573
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History